Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.59 Insider Own3.62% Shs Outstand55.04M Perf Week-4.90%
Market Cap53.42M Forward P/E- EPS next Y-0.02 Insider Trans0.00% Shs Float53.08M Perf Month-35.76%
Income-87.26M PEG- EPS next Q-0.29 Inst Own18.37% Short Float / Ratio0.04% / 0.13 Perf Quarter20.78%
Sales0.00M P/S- EPS this Y59.85% Inst Trans- Short Interest0.02M Perf Half Y-14.16%
Book/sh2.32 P/B0.42 EPS next Y97.80% ROA-46.09% Target Price6.87 Perf Year35.38%
Cash/sh2.38 P/C0.41 EPS next 5Y- ROE-51.10% 52W Range0.53 - 2.84 Perf YTD11.78%
Dividend- P/FCF- EPS past 5Y-80.56% ROI-68.01% 52W High-65.85% Beta-0.80
Dividend %- Quick Ratio9.26 Sales past 5Y0.00% Gross Margin- 52W Low81.41% ATR0.26
Employees100 Current Ratio9.26 Sales Q/Q- Oper. Margin0.00% RSI (14)38.84 Volatility12.21% 21.11%
OptionableYes Debt/Eq0.00 EPS Q/Q50.60% Profit Margin- Rel Volume1.38 Prev Close0.99
ShortableYes LT Debt/Eq0.00 EarningsSep 12 AMC Payout- Avg Volume176.37K Price0.97
Recom1.00 SMA20-35.53% SMA50-21.89% SMA200-11.16% Volume243,875 Change-1.76%
Date Action Analyst Rating Change Price Target Change
Apr-13-21Initiated SVB Leerink Outperform $32
Apr-13-21Initiated Piper Sandler Overweight
Apr-13-21Initiated Jefferies Buy $27
Nov-30-23 09:45AM
Nov-28-23 09:40AM
Nov-21-23 07:32AM
04:41PM Loading…
Nov-20-23 04:41PM
Nov-06-23 09:40AM
Oct-20-23 09:40AM
Sep-15-23 12:00PM
Sep-12-23 04:15PM
Aug-24-23 06:21PM
Jul-10-23 08:00AM
Jul-05-23 04:05PM
Jun-01-23 04:05PM
04:05PM Loading…
Apr-11-23 04:05PM
Mar-20-23 09:24AM
Mar-18-23 02:40PM
Mar-17-23 04:38PM
Mar-06-23 08:15AM
Feb-06-23 08:30AM
Jan-16-23 05:13AM
Dec-30-22 07:30AM
Dec-19-22 08:00AM
Dec-02-22 05:00PM
Oct-27-22 04:05PM
Oct-04-22 11:40AM
04:10PM Loading…
Oct-03-22 04:10PM
Sep-13-22 04:30PM
Sep-01-22 08:00AM
Aug-30-22 09:36AM
Aug-08-22 12:19PM
Jul-12-22 06:02AM
Jul-11-22 04:05PM
Jun-17-22 04:05PM
Jun-08-22 12:00PM
Jun-02-22 04:05PM
May-17-22 04:05PM
May-04-22 07:43AM
May-03-22 04:05PM
May-02-22 02:02PM
Mar-31-22 04:05PM
Mar-01-22 08:00AM
Feb-09-22 07:00AM
Jan-24-22 07:00AM
Jan-05-22 07:00AM
Jan-04-22 04:05PM
Dec-25-21 02:38AM
Nov-25-21 07:35AM
Nov-22-21 08:00AM
Nov-19-21 02:47PM
Nov-18-21 04:02PM
Nov-11-21 08:00AM
Oct-19-21 08:00AM
Sep-08-21 08:00AM
Sep-02-21 08:00AM
Aug-31-21 04:05PM
Aug-25-21 08:00AM
Aug-23-21 04:05PM
Jun-11-21 03:57PM
May-26-21 08:00AM
May-25-21 08:00AM
May-12-21 08:00AM
Apr-08-21 08:00AM
Mar-23-21 04:05PM
Mar-18-21 11:58PM
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.